Paolo Carlini
Yahoo!
145 Papers
1.5K Citations
Paolo Carlini is an academic researcher from Yahoo!. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 32, co-authored 141 publications.
Chat about Author
Papers
Meta-analysis of the randomized comparisons between low-molecular weight heparin (LMWH) with oral anticoagulants (OA) for the long-term treatment of symptomatic venous thromboembolism (VTE): no difference in cancer-related mortality
Gianluigi Ferretti,Emilio Bria,Paolo Carlini,Alessandra Felici,Diana Giannarelli,Mariangela Ciccarese,F.L. Cecere,Nello Salesi,B. Di Cocco,Francesco Cognetti +9 more
TL;DR: In this article, a long-term low-molecular-weight heparin (LMWH) regimen was proposed, which is administered once-daily and does not require any anticoagulant monitoring.
2
MRI Evaluation Using DWI and T2WI of Residual Lymph Nodes in patients Affected by Head and Neck Squamous Cell Carcinoma Treated with Chemo-Radiotherapy
Francesca Piludu,Emma Gangemi,Laura Marucci,Antonino Guerrisi,Raul Pellini,Renato Covello,Paolo Carlini,Giuseppe Spriano,Giuseppe Sanguineti,Simona Marzi,Antonello Vidiri +10 more
2
Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer?
Paola Papaldo,Serena Di Cosimo,Gianluigi Ferretti,Paolo Carlini,Alessandra Fabi,Fabiana Letizia Cecere,Francesco Cognetti +6 more
TL;DR: Interestingly, ER expression was not a negative prognostic factor, even among women <35 years, the 5-year disease-free survival (DFS) tending to be higher in patients with ER-positive rather than -negative BC, and the potential of combining anthracyclines and endocrine therapies is reviewed.
2
Timing of adjuvant chemotherapy by menstrual cycle phase and risk of secondary amenorrhea in women with early breast cancer: Preliminary results
A. Alimonti,S. Di Cosimo,Gianluigi Ferretti,Paolo Carlini,Paola Papaldo,A. Fabi,Alain Gelibter,Isabella Sperduti,L. Di Lauro,Francesco Cognetti +9 more
TL;DR: An enhanced ability to predict the likelihood of CIA may facilitate decision-making facing the tradeoffs between beneficial and detrimental effects of adjuvant therapy, especially in young patients with good prognosis.
2
Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: Pooled-analysis of 8,794 patients
Mariangela Ciccarese,Emilio Bria,Diana Giannarelli,Federica Cuppone,Carmen Nuzzo,Cecilia Nisticò,E. Terzoli,Francesco Cognetti,Paolo Carlini +8 more
TL;DR: All the available phase III trials are considered, the early switch strategy improves survival over standard tamoxifen for 5 years, with a different toxicity profile.
2